<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/843130C9-057D-4403-8281-EA057685461B"><gtr:id>843130C9-057D-4403-8281-EA057685461B</gtr:id><gtr:name>University Children's Hospital Munster</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0DA4641-E6E8-416B-B33A-1544E14DEFA7"><gtr:id>A0DA4641-E6E8-416B-B33A-1544E14DEFA7</gtr:id><gtr:name>Connecticut College</gtr:name><gtr:address><gtr:line1>Connecticut College</gtr:line1><gtr:line2>270 Mohegan Avenue</gtr:line2><gtr:postCode>CT 06320</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Haematology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/843130C9-057D-4403-8281-EA057685461B"><gtr:id>843130C9-057D-4403-8281-EA057685461B</gtr:id><gtr:name>University Children's Hospital Munster</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0DA4641-E6E8-416B-B33A-1544E14DEFA7"><gtr:id>A0DA4641-E6E8-416B-B33A-1544E14DEFA7</gtr:id><gtr:name>Connecticut College</gtr:name><gtr:address><gtr:line1>Connecticut College</gtr:line1><gtr:line2>270 Mohegan Avenue</gtr:line2><gtr:postCode>CT 06320</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D656E076-ACC9-473D-9450-E83BF6F1FB4D"><gtr:id>D656E076-ACC9-473D-9450-E83BF6F1FB4D</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Pule</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501935"><gtr:id>6748D91D-2D2B-4BF2-8651-F96AA48DD266</gtr:id><gtr:title>Genetic Engineering of T-cells for Adoptive Immunotherapy of Chronic Lymphocytic Leukemia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0501935</gtr:grantReference><gtr:abstractText>The immune system is highly effective at removing large-numbers of virally infected cells without damaging normal non-infected tissues, however it often remains unresponsive to cancer cells. In this project, we plan to modify T-cells, a key component of the immune system, so that they kill established cancers. We propose taking normal T-cells from patients with a form of cancer known as chronic lymphocytic leukaemia (CLL), and genetically engineer them in the laboratory so that they kill the leukaemia cells, with a view to ultimately giving them back to the patient as a treatment. This engineering exploits our detailed understanding of how the immune system works. In a sense we will use nature?s toolkit to create a cancer killing immune response. We will test these T-cells in mice with human leukaemias, to establish safety and effectiveness of this new form of treatment. We plan to use the data amassed from this project to prepare the ground-work for a clinical study in patients with CLL that have failed standard treatment. This work represents the beginning of a new field of therapy, where T-cells can be engineered to specifically remove harmful cell populations without damaging healthy normal tissue</gtr:abstractText><gtr:technicalSummary>Administration of tumor-specific T-cells (adoptive immunotherapy) has proven to be an effective cancer treatment but is limited by the difficulty in selecting and expanding tumour-specific T-cells to all but a few malignancies. Genetic modification of T-cells with chimeric T-cell receptors (cTCRs), allows us to graft T-cells with any desired specificity, overcoming this limitation. In fact, cTCRs allow radical avenues of immunotherapy such as the generation of large numbers of T-cells recognizing tissue-specific self antigens. CD19 is a B-cell surface antigen expressed by nearly all B-cells and B-cell malignancies. We have developed a CD19 specific cTCR - we plan to build on this receptor to engineer autologous T-cells into an effectively therapy for Chronic Lymphocytic Leukemia (CLL), a common malignancy which remains predominantly incurable. 

To accomplish this, we aim to (1) improve the cTCR itself, (2) to engineer T-cell to release a cytokine payload, (3) to incorporate a suicide gene into the retroviral vector, (4) to test the contribution of these components in an animal model and finally (5) to perform preparatory work for a phase I clinical study. (1) Co-stimulatory signals are essential to induce an effective and lasting immune response but are frequently not supplied by tumour cells. By introducing portions of co-stimulatory molecules into the intracellular portion of cTCRs it is possible to generate cTCRs which transmit co-stimulatory signals. We will generate CD19 specific cTCRs which transmit synergistic CD28 and OX40 co-stimulatory signals in cis. (2) By driving expression of a cytokine from Nuclear Factor of Activated T-cell (NF-AT) response elements in our retroviral vector, we can engineer T-cells to release cytokines upon activation (i.e. at the site of tumour). We plan to use our engineered T-cells to deliver IL-12, a potent activator of both innate and adaptive immunity increasing efficacy without systemic toxicity. (3) To improve safety in clinical studies, a means of removing adoptively transferred T-cells in case of adverse events is desirable. In the same vector, we will co-express a form of capase 9 which can be activated by exposure to an otherwise inert small-molecule chemical inducer of dimerization (CID). 

(4) The safety and efficacy of these modifications will be tested sequentially in a suitable animal model, using bioluminescence to track adoptively transferred T-cells in vivo. (5) Finally, we will establish the processes required for large-scale production of clinical grade vector and transduced T-cells under Good Manufacturing Practise conditions. 

Scientifically, with this fellowship, we hope test what is required immunologically to target tissue-specific self-antigens in this manner. Medically, this fellowship should form the pre-clinical data for an innovative phase I clinical study.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>607245</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Children's Hospital Munster</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Chimeric Receptor Collaboration with University of Muenster</gtr:description><gtr:id>D5F127D3-D4EA-41C3-AF81-2829C6D19FC7</gtr:id><gtr:impact>Two publications so far - PMID: 19638467 and PMID: 19360406</gtr:impact><gtr:outcomeId>CEB213F5ACF-1</gtr:outcomeId><gtr:partnerContribution>Reagents and expertise.</gtr:partnerContribution><gtr:piContribution>We provide chimeric antigen receptor and retroviral vector constructs. University of Muenster do the cell biology work.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellectis</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Cellectis Therapeutics</gtr:description><gtr:id>21EEA10F-B7F2-4C82-AF4F-FDF218AC481F</gtr:id><gtr:impact>Cellectis and UCL form the core of the FP7 ATECT consortium. We are getting close to implementing a clinical study.</gtr:impact><gtr:outcomeId>sCsykYDWNFw-1</gtr:outcomeId><gtr:partnerContribution>We are working together to make a universal CAR T-cell platform. We are doing some of the pre-clinical work and the study will be on our site (UCLH)</gtr:partnerContribution><gtr:piContribution>Industrial collaboration with Cellectis therapeutics. Sponsored research and licensing of our IP</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Adoptive Immunotherapy of Paediatric Cancer with Engineered T-cells</gtr:description><gtr:id>C63E1591-8523-4687-9339-1854D2574695</gtr:id><gtr:impact>Publication - PMID: 1882956</gtr:impact><gtr:outcomeId>63D248042E8-1</gtr:outcomeId><gtr:partnerContribution>Expertise and reagents.</gtr:partnerContribution><gtr:piContribution>We perform molecular cloning, protein engineering and retroviral vector work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Immunosuppression resistant T-cells</gtr:description><gtr:id>B74C19EC-FC93-42B9-81A9-B81EB6A730C4</gtr:id><gtr:impact>UCL./UCLH CBRC Grant awarded
Publication PMID: 19770360</gtr:impact><gtr:outcomeId>3625D40B9F6-1</gtr:outcomeId><gtr:partnerContribution>Shared PhD student. Complementary research experience.</gtr:partnerContribution><gtr:piContribution>Working together using our different strengths - my lab working on protein engineering / retroviral vector; ICH lab working on cell biology aspects</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Stretch Luciferins</gtr:description><gtr:id>69AB6B06-F5DB-48AC-A9F1-4D9A4A780450</gtr:id><gtr:impact>Generated many new compounds and engineered Luciferases and used this preliminary data to submit a project grant to the BBSRC</gtr:impact><gtr:outcomeId>RpjhzL9fwxM-1</gtr:outcomeId><gtr:partnerContribution>Preliminary data and project grant to BBSRC</gtr:partnerContribution><gtr:piContribution>We have generated libraries of Firefly Luciferases to &amp;quot;fit&amp;quot; around novel Luciferin (substrate) generated by organic chemistry in an attempt to generate a very bright but highly red-shifted emission for in vivo imaging.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>T-cell Tracking in vivo with PET</gtr:description><gtr:id>29EAED12-16EE-4AC0-AC6F-217B7CA803C3</gtr:id><gtr:impact>Fasttrack UCL grant worth &amp;pound;45000 with aim to apply for more substantive project grant next year</gtr:impact><gtr:outcomeId>4B3D231DF55-1</gtr:outcomeId><gtr:partnerContribution>Providing novel chemical radiotracers</gtr:partnerContribution><gtr:piContribution>My lab carries out protein engineering work to make molecular pumps to pump novel radiochemicals made by my collaborator. This work is completely complementary.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Connecticut College</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Bioluminesce work to track T-cells in vivo</gtr:description><gtr:id>EB3B0D34-136F-4B6D-A95E-1597583A9E2F</gtr:id><gtr:impact>Publication - PMID: 19748472</gtr:impact><gtr:outcomeId>A00CF4E5FB9-1</gtr:outcomeId><gtr:partnerContribution>New reagents.</gtr:partnerContribution><gtr:piContribution>We worked together to develop optimal luciferases for mammalian cell expression which are red shifted to give best tissue penetration of light for bioluminescence. We are experts at codon optimization and mammalian cell expression vectors while Connecticut College engineered luciferases.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biochemical Engineering</gtr:department><gtr:description>Genetic Reporters for Photoacoustic Imaging</gtr:description><gtr:id>F1D6DA85-47D5-4999-A646-67B0F23155F8</gtr:id><gtr:impact>We have generated considerable preliminary data and have submitted a grant to the BBSRC and just publish our findings soon.</gtr:impact><gtr:outcomeId>Fk8iUUFCFJo-1</gtr:outcomeId><gtr:partnerContribution>We have identified pigment proteins which when transgenically expressed can allow selective imaging of marked cells by Photoacoustic Imaging. We worked together to generate considerably preliminary data and have submitted a project grant to the BBSRC.</gtr:partnerContribution><gtr:piContribution>Biomedical Engineering at UCL have pioneered a new imaging modality called photoacoustic imaging which uniquely allows imaging of cellular resolution at cm depth. We have worked with these engineers and identified several pigment proteins from coral which when transgenically expressed should allow selective detection of marked cells in vivo.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CD160 targeting with QMUL</gtr:description><gtr:id>98833037-ADCA-4620-B68E-1F8F5B34087F</gtr:id><gtr:impact>CRUK Project grant to start next year</gtr:impact><gtr:outcomeId>VBqW8TshMqV-1</gtr:outcomeId><gtr:partnerContribution>Them: target validation; Us - expertise in immunotherapy</gtr:partnerContribution><gtr:piContribution>I have teamed up with Samir Agrewal in QMUL to develop new immunotherapeutics against CLL which target CD160</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ATTACK-CANCER Meeting 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F7FD028F-0F27-4C69-852C-BFF3C6A2906E</gtr:id><gtr:impact>This is *the* T-cell engineering meeting and I was invited to speak once again

Several offers of collaboration</gtr:impact><gtr:outcomeId>YvtDz1m4atM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.attack-cancer.org/Symposium2/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Leukemia Research Fund Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AC5A9D0D-A864-4041-BC3D-987D838FEF84</gtr:id><gtr:impact>The LLR open day in the Cancer Institute involved members of the public involved in raising funds for this charity visiting the labs, hearing talks and participating in scientific demonstrations

I was encouraged by the positive reception to submit another grant to the LLR</gtr:impact><gtr:outcomeId>QnaGxgLuvF5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sparks Neuroblastoma Family Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>FD643077-266D-4CBD-9526-0077F57404D3</gtr:id><gtr:impact>SPARKS is a children's cancer charity had a family day and invited me to talk about chimeric antigen receptors to treat cancer, in particular, neuroblastoma.

I may be able to secure funding from SPARKS for future clinical studies.</gtr:impact><gtr:outcomeId>510CF4E722D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Haematology - invited presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>0BE0012A-9E12-4198-B0C7-50DC977B545E</gtr:id><gtr:impact>Invited speaker at British Society of Haematology meeting.

Made many contacts to recruit patients to future clinical studies.</gtr:impact><gtr:outcomeId>3411A0E3394</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>193154</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Project Grant</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>D3C3FBBA-0661-472C-9D68-29AFAC423134</gtr:id><gtr:outcomeId>4025A0596000</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>ATECT consortium</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>Project #602239</gtr:fundingRef><gtr:id>65DA8F58-5197-4A48-A4B9-660D50DDA4F4</gtr:id><gtr:outcomeId>gbEfWapos2i</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR, Vector Production Costs Grant</gtr:description><gtr:end>2008-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>5CBA64CB-E640-4569-9646-F90FF3B079A1</gtr:id><gtr:outcomeId>2E8D2C539EC0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>360000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Clinical Trial Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>E1A53217-CDC1-4878-A9C9-962DF36FBC18</gtr:id><gtr:outcomeId>4499501EE160</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44773</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Fasttrack Application Clinical Research</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>4A918299-C6A1-4609-A50B-A686551AC7C8</gtr:id><gtr:outcomeId>6B66E423AFD0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GD2 CAR T-cells for Neuroblastoma (NAC) NOte this is milestoned i.e. not all funding at once</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>EA95AF0E-B7CA-47BB-81F8-AB83843E549C</gtr:id><gtr:outcomeId>Q8z3GSNbM420</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44994</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR, new targets FSC029 Anti-Cancer T cells engineered using Boolean logic gates</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>03AD9E76-0DEE-493F-BEB4-A3EA61A1151B</gtr:id><gtr:outcomeId>nCh8iQmhXU60</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>440000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Genetically encodable contrast agents for Photoacoustic imaging</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>1745E3A3-0927-4318-A4CB-CAB0A104D646</gtr:id><gtr:outcomeId>q3J3ek6Uo9q0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>127717</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU Marie Curie Fellowship</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>24AF4500-D4ED-44DF-9D90-288A688B236F</gtr:id><gtr:outcomeId>ENm5rqV6umj0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>271997</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>CBRC/SBRC Collaborative Funding Call</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>6E68662A-0FA0-4232-9E7E-931B5A0EDA90</gtr:id><gtr:outcomeId>01492AA068B0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>420724</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Synthetic Biology in T-cells</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/J018899/1</gtr:fundingRef><gtr:id>9E43AF71-CD74-4F12-81EA-FE983B268A52</gtr:id><gtr:outcomeId>c3k2azMPMe9</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Compact Sort Suicide gene for T-cell therapy</gtr:description><gtr:id>11512A90-8159-4D15-8CEE-481BBCB51B9E</gtr:id><gtr:impact>Cheaper safer Cancer gene therapy with T-cells</gtr:impact><gtr:outcomeId>bWb2qJLS6Fv</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>RQR8</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Pule-Pizzey Synthesis Device is a prototype to generate arbitrary DNA polynucleotides at high fidelity. Development has been funded by an innovation grant from the College (UCL Biomedica). Phase I prototype has been constructed.</gtr:description><gtr:id>D53315BE-A7CA-42A5-ABFA-B0251C875D9C</gtr:id><gtr:impact>Such a device could revolutionize biological research by replacing laborious molecular cloning techniques with the ability to make arbitrary synthetic DNA.</gtr:impact><gtr:outcomeId>ZPRnA76xAMd</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Pule-Pizzey Synthesis Device</gtr:title><gtr:type>Products with applications outside of medicine</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A family of Chimeric Antigen Receptors which recognized CD19 have been generated. They have been distributed to investigators in Italy, Norway and Germany.</gtr:description><gtr:id>E927A8E1-8738-4BFC-A9AE-433C13EF7141</gtr:id><gtr:impact>Chimeric Antigen Receptors are one the basic tools for adoptive immunotherapy with engineered T-cells. CD19 is one the most promising targets. These receptors are useful for this field.</gtr:impact><gtr:outcomeId>E47785EAC4D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>anti-CD19 Chimeric Antigen Receptors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Highly compact epitope based selectable marker and suicide gene for use in engineered T-cell therapy</gtr:description><gtr:id>C30DD026-EDC6-4F2B-8F27-968CA2281382</gtr:id><gtr:impact>This will allow T-cell therapy studies to be safer, easier and cheaper.</gtr:impact><gtr:outcomeId>GnoRuksFxDJ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RQR8</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Retroviral expression plasmids coding for mutant Calcineurins which render cells resistant to immunosuppressive medications Tacrolimus and Ciclosporin. Have been provided to Marcel Van den Brink MSKCCC and submitted to addgene.org</gtr:description><gtr:id>685ACC73-CB34-4525-9CBA-EE7D097262C2</gtr:id><gtr:impact>T-cells can be engineered to be resistant to Tacrolimus and Ciclosporin. This has impact to (1) immunotherapeutic strategies in the face of ongoing immunosuppression (i.e. bone-marrow or solid organ transplant), (2) useful in vivo experimental tool where subsets of T-cells can be selected</gtr:impact><gtr:outcomeId>809739854EA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Calcineurin Mutants</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>133F6AB9-90B2-4374-8A62-B8E3538E2BFC</gtr:id><gtr:title>Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37f7707194fa120d13e01c91cde34b6b"><gtr:id>37f7707194fa120d13e01c91cde34b6b</gtr:id><gtr:otherNames>Brewin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>982EB100634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6C82F02-BEF8-4767-ABE6-4713CB6AE23B</gtr:id><gtr:title>Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bb44055addc49aa0cd8597bab6d63be"><gtr:id>7bb44055addc49aa0cd8597bab6d63be</gtr:id><gtr:otherNames>Samarasinghe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>4F879D03B8F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24F2D616-A6ED-477A-8B7F-C8BCF60758C2</gtr:id><gtr:title>Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8241cd65c3aec3a165a4001a54e629e8"><gtr:id>8241cd65c3aec3a165a4001a54e629e8</gtr:id><gtr:otherNames>Yan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>10EF8284F21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3204180-210C-4897-9667-C11B1E27C801</gtr:id><gtr:title>2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16378f96c1cebbc6cc43f9bef236e4c9"><gtr:id>16378f96c1cebbc6cc43f9bef236e4c9</gtr:id><gtr:otherNames>Altvater B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>639DB600F92</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E3CE682-D7A9-4718-8E9E-2BE3C602AAAA</gtr:id><gtr:title>Transiently redirected T cells for adoptive transfer.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e56eb5e374824049bcc4ba045325c18"><gtr:id>4e56eb5e374824049bcc4ba045325c18</gtr:id><gtr:otherNames>Alm?sbak H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>hKimuSRJKhH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46ADFC56-A0BF-4E29-B8ED-1438EA2941A0</gtr:id><gtr:title>Red-emitting luciferases for bioluminescence reporter and imaging applications.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb5c11a517c27cd4856db72d1ab13d98"><gtr:id>cb5c11a517c27cd4856db72d1ab13d98</gtr:id><gtr:otherNames>Branchini BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>9915A41A3A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C04CB3A3-18FE-44FB-A636-89D410334E61</gtr:id><gtr:title>2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16378f96c1cebbc6cc43f9bef236e4c9"><gtr:id>16378f96c1cebbc6cc43f9bef236e4c9</gtr:id><gtr:otherNames>Altvater B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>1A1D312B51E</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501935</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>